Skip to content

Preventive effect of FLUVAR® on COVID-19

Evaluation of the effect of FLUVAR® in respiratory dosage form on the prevention of COVID-19 respiratory infection

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200404046932N2
Enrollment
1000
Registered
2021-10-30
Start date
2020-04-20
Completion date
Unknown
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Prophylaxis. COVID-19, virus not identified

Interventions

Intervention 1: Intervention group 1: Three puffs of FLOVAR® spray on each side, equivalent to a total of 500µl of medicine, once a week and receiving an additional dose of medicine in case of contact

Sponsors

Hakiman e Shargh Research Co.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 18 years and older Informed consent

Exclusion criteria

Exclusion criteria: History of moderate or severe asthma Participating in another clinical trial for COVID-19

Design outcomes

Primary

MeasureTime frame
Rate of COVID-19 infection. Timepoint: Time Frame: 14-20 months after admission to the study. Method of measurement: Acquisition of COVID-19 infection as confirmed by positive PCR swab taken 3-5 days after symptom onset.

Secondary

MeasureTime frame
Duration and intensity of COVID-19 symptoms of infected participants. Timepoint: Two weeks after onset of disease symptoms. Method of measurement: Questionnaire of symptoms, duration and intensity of disease.;Side effects of intervention. Timepoint: Duration of Study. Method of measurement: Questionnaire of side effects.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Safaeian

Esfahan University of Medical Sciences

leila_safaeian@pharm.mui.ac.ir+98 31 3792 7087

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026